ArticleOncoimmunology2022
Article in Oncoimmunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Upregulation of paraoxonase-2 enzyme in human osteosarcoma and its involvement in mechanisms promoting the aggressive behavior of tumor cells.Molecular biology reports · 2026Article
- Paraoxonase 2 as a target for aging-related diseases.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026Review
- GNAQ inhibits tumorigenesis via the ARHGEF25-mediated RHOA pathway in NK/T-cell lymphoma.Cancer biology & therapy · 2025Article
- Role of paraoxonase 2 (PON2) as a potential biomarker and therapeutic target in cancer treatment.Journal of cancer research and clinical oncology · 2025Review
- Circulating Tumour DNA Is a Biomarker of Response in Angioimmunoblastic T-Cell Lymphoma.International journal of molecular sciences · 2025Article
- Ten-Eleven Translocation Family Proteins: Structure, Biological Functions, Diseases, and Targeted Therapy.MedComm · 2025Review
- Binding of RHOA G17V to p300 enhances its HAT activity: a new mechanism of epigenetic deregulation in TFH lymphoma.Blood advances · 2025Article
- Application of urine proteomics in the diagnosis and treatment effectiveness monitoring of early-stage Mycosis Fungoides.Clinical proteomics · 2024Article
- Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma.Clinical and experimental medicine · 2023Review
- Genome-Wide Analysis of Sheep Artificially or Naturally Infected with Gastrointestinal Nematodes.Genes · 2023Article
- Prognostic prediction of lung adenocarcinoma by integrative analysis of RHOH expression and methylation.The clinical respiratory journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angioimmunoblastic T-cell lymphoma (AITL) is a malignant hematologic tumor arising from T follicular helper (Tfh) cells. High-throughput genomic sequencing studies have shown that AITL is characterized by a novel highly recurring somatic mutation in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.